STOCK TITAN

Provectus Biopharms (PVCT) DEF 14A Filings

PVCT OTC

Here are the DEF 14A proxy statements from Provectus Biopharms (PVCT) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow PVCT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PVCT filings page.

Rhea-AI Summary

Provectus Biopharmaceuticals, Inc. is asking stockholders to approve several key corporate and governance items at its 2026 annual meeting. The in‑person meeting is scheduled for June 18, 2026 in Knoxville, Tennessee, with a record date of April 20, 2026.

Stockholders will vote to elect four directors, approve on an advisory basis the compensation of named executive officers, and ratify CBIZ CPAs P.C. as independent auditor for 2026. The proxy details executive pay, including 2025 base salaries of $240,000 for the CEO and President and $200,000 for the CFO, plus prior large stock option grants under the 2024 Equity Compensation Plan.

The most structural proposals would authorize the board to implement a reverse stock split of common stock, Series D Preferred, and Series D‑1 Preferred at a ratio between 1‑for‑10 and 1‑for‑50, and, only if that split is approved, to proportionally reduce authorized common and preferred shares. As of the record date, there were 420,279,879 common shares outstanding, along with 956,985 Series D and 14,389,027 Series D‑1 shares. The board unanimously recommends voting “FOR” all five proposals.